Guidance in words, not numbers.

We lock a binary: Sun Pharma's reported consolidated revenue growth for fiscal 2027 is 5.0% or higher year-on-year. Confidence 92% — the highest in this tranche.

Guidance is high single digits, which we read as approximately 7-9%. Q1 delivered 10.46%. Our threshold sits below both, and below the bottom of any reasonable reading of the guidance phrase.

Most locks in this series anchor to a published numeric range. Sun Pharma did not give one. It said high single digits, which is a relative guide — a company describing the shape of its year without committing to a decimal.

This series treats that as a legitimate but distinct anchoring basis, the same one used for DBS at P-260 and RELX at P-278, and the criterion says so rather than pretending a number was published. The method is to read the phrase conservatively, take the lowest defensible interpretation, and then set the threshold below even that. High single digits most naturally means 7-9%; a hostile reading might stretch it to 6%. The lock sits at 5.0%, under every one of those readings.

That conservatism is why the confidence is 0.92 rather than the 0.89-0.91 elsewhere in this tranche. It is also why the lock carries less information than a numerically-anchored one: a wide margin against a vague guide is a safer call and a less interesting one, and both halves of that sentence are true.

The same quarter contains genuinely opposing movements. India formulations grew 16% to INR 5,475 crore and now contribute 36.1% of consolidated revenue. Specialty sales grew 12.8% to US$351m, reaching 21.9% of revenue. US formulation sales fell to US$427m on weak generics demand and the loss of limited exclusivity for lenalidomide.

A brief could pick any of those and tell a coherent story: Sun Pharma is compounding at 16%, or Sun Pharma's largest export market is shrinking. Both sentences are defensible from the same filing. This is the naming problem the series has hit repeatedly, most sharply at Roche in P-258 where two bases produced opposite signs on the same result.

The lock therefore names consolidated revenue growth in rupees, the group-level figure that nets all of it, and the scoring block rules out the segment and currency alternatives explicitly. The known drag is real — the lenalidomide exclusivity loss is a structural step-down rather than a soft quarter, and US generics weakness may persist — which is precisely what the 5.0% floor absorbs.

The residual 8% is a sharper-than-expected US erosion coinciding with an Indian slowdown, or a currency translation effect that compresses the consolidated rupee line.